Drug Profile
Sibofimloc - Enterome/Takeda
Alternative Names: EB-8018; TAK-018Latest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Developer Enterome; Takeda
- Class Anti-inflammatories; Fluorenes; Hepatoprotectants; Ketones; Piperidines; Pyrans; Small molecules; Spiro compounds
- Mechanism of Action E coli fimH protein inhibitors; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Crohn's disease
- No development reported Gastrointestinal disorders; Liver disorders
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in United Kingdom (PO)
- 28 Jun 2023 No recent reports of development identified for preclinical development in Liver-disorders in United Kingdom (PO)
- 25 Aug 2022 Takeda terminates the phase IIa SYMMETRY trial in Crohn's disease in Austria, United Kingdom, France, Germany, Netherlands and USA (PO) due to sponsor decision to discontinue study due to inability to recruit the expected number of subjects within the requisite time period (EudraCT2019-000886-19) (NCT03943446)